Molecular Profiles Chosen to Develop Topical and Oral Formulations of Telormedix's Psoriasis Product - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Molecular Profiles Chosen to Develop Topical and Oral Formulations of Telormedix's Psoriasis Product


Molecular Profiles, a Nottingham-based CDMO, has secured a major pan-European formulation project, in which the company will be responsible for developing a topical and an oral formulation for Telormedix’s psoriasis products, TMX-302. The international research project, known as PAT (Psoriasis Anti-inflammatory Treatment), will also involve other consortium partners Biopta, Midatech Biogune and the University Hospital Zurich.

Telormedix, a clinical stage biopharmaceutical company, has raised funding from the European Eurostars Programme to coordinate the TMX-302 project, which will use Midatech’s glycan-coated gold nanoparticles formulated using Molecular Profiles’ expertise. 
Johanna Holldack, CEO at Telormedix, said in a press statement that “the team at Molecular Profiles will play a key role in developing new oral and topical formulations of TMX-302, both of which are viewed as practicable administration options for the treatment of psoriasis.”



Just a few weeks ago, Molecular Profiles announced the official opening of its new clinical manufacturing facility following a successful inspection from the Medical and Healthcare products Regulatory Agency (MHRA). Molecular Profiles was also recently acquired by Columbia Laboratories, a Boston-based drug development company.

“We are pleased to have been chosen as the formulation development partner for this high-profile, multi-partner project,” said Nikin Patel, CEO of Molecular Profiles in a press statement. “Our team is ready to apply our technologies to deliver a robust topical and oral formulation.”
 The company’s new facility can handle a range of dosage forms such as solids, liquids, semi-solids and inhaled products and has the capacity to manufacture controlled drugs and highly potent compounds up to OEB 4 level with batch scale of up to 30kg.

Source: Molecular Profiles

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
25%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
36%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here